Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001415889-25-021501
Filing Date
2025-08-12
Accepted
2025-08-12 16:57:37
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 14132
2 JOINT FILING AGREEMENT ex-99-08122025_080838.htm EX-99.1 22778
  Complete submission text file 0001415889-25-021501.txt   38395
Mailing Address UCLA SCHOOL OF MEDICINE 10833 LE CONTE 66-118 CHS BOX 951738 LOS ANGELES CA 9095-1738
Business Address
Belldegrun Arie (Filed by) CIK: 0001296549 (see all company filings)

Type: SCHEDULE 13G/A

Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Subject) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90685 | Film No.: 251207639
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)